Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - AKCEA THERAPEUTICS, INC. | d805386dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 2019
Akcea Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
| Delaware | 001-38137 | 47-2608175 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 22 Boston Wharf Road 9th Floor Boston, MA |
02210 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (617) 207-0202
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| Common stock | AKCA | NASDAQ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01. | Other Events. |
On December 18, 2019, Akcea Therapeutics, Inc. (the “Company”) announced that, following a strategic portfolio decision by Novartis Pharma AG (“Novartis”) not to exercise its option, the Company has retained rights to develop and commercialize AKCEA-APOCIII-LRx. In accordance with the terms of the Strategic Collaboration, Option and License Agreement between Novartis and the Company dated January 5, 2017, Novartis’ rights to develop and commercialize AKCEA-APOCIII-LRx are terminated. A copy of the press release is attached to this Report as Exhibit 99.1 and is incorporated by reference into this Item 8.01.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit |
Description | |
| 99.1 | Press Release, dated December 18, 2019, issued by the Company | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| AKCEA THERAPEUTICS, INC. | ||||||
| Date: December 19, 2019 | By: | /s/ Damien McDevitt | ||||
| Damien McDevitt | ||||||
| Interim Chief Executive Officer | ||||||